Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Journal of Hematology & Oncology volume 16, Article number: 79 (2023)
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL).
Thirteen patients were treated with escalating doses of CD19-directed CARTs between 1 × 106 and 50 × 106 CARTs/m2. Leukapheresis, manufacturing and administration of CARTs were performed in-house.
For all patients, CART manufacturing was feasible. None of the patients developed any grade of Immune effector cell-associated neurotoxicity syndrome (ICANS) or a higher-grade (≥ grade III) catokine release syndrome (CRS). CART expansion and long-term CART persistence were evident in the peripheral blood (PB) of evaluable patients. At end of study on day 90 after CARTs, ten patients were evaluable for response: Eight patients (80%) achieved a complete remission (CR), including five patients (50%) with minimal residual disease (MRD)-negative CR. Response and outcome were associated with the administered CART dose. At 1-year follow-up, median overall survival was not reached and progression-free survival (PFS) was 38%. Median PFS was reached on day 120. Lack of CD39-expression on memory-like T cells was more frequent in CART products of responders when compared to CART products of non-responders. After CART administration, higher CD8 + and γδ-T cell frequencies, a physiological pattern of immune cells and lower monocyte counts in the PB were associated with response.
In conclusion, third-generation CARTs were associated with promising clinical efficacy and remarkably low procedure-specific toxicity, thereby opening new therapeutic perspectives for patients with r/r ALL.
Trial registration This trial was registered at www.clinicaltrials.gov as NCT03676504.
Chimeric antigen receptor T cell (CART) products targeting CD19 have been approved for the treatment of patients with relapsed and/or refractory (r/r) B cell malignancies [1,2,3,4], including patients with acute lymphoblastic leukemia (ALL) [2, 3].
All commercially available CARTs express second-generation CARs that contain one costimulatory domain. Third-generation CARTs comprising two costimulatory domains have shown superior engraftment, improved expansion capacity and prolonged persistence [5,6,7,8,9]. Clinically, superior expansion and longer persistence were observed when CD19-directed second (CD28 costimulatory domain)- and third-generation (CD28 and 4-1BB) CARTs were simultaneously administered to lymphoma patients . However, clinical data evaluating solely third-generation CARTs are limited .
Here, we describe the first results obtained with an academically developed third-generation CAR in the framework of the investigator-initiated trial (IIT) Heidelberg CAR number 1 (HD-CAR-1) in adult patients with r/r ALL. All steps of treatment including leukapheresis, manufacturing and administration of CARTs, patient monitoring as well as patient follow-up were performed in-house.
A solely academic-driven trial, a third-generation Good Manufacturing Practice (GMP) grade retroviral vector and treatment of adult r/r ALL patients with escalating CART doses make this trial hitherto unique.
Adult patients with confirmed CD19-positive, minimal residual disease (MRD)-positive, hematological or extramedullary r/r ALL received escalating doses of autologous T-lymphocytes retrovirally transduced with a third-generation CD19-directed CAR (RV-SFG.CD19.CD28.4-1BBzeta) . Endpoints included feasibility of manufacturing and treatment safety, clinical efficacy and survival. Patients were evaluated as outlined in the study calendar . Written informed consent was obtained from all patients prior to treatment. The trial was conducted according to the principles of the Declaration of Helsinki.
HD-CAR-1 CART manufacturing
As described [12, 13], patients underwent leukapheresis for collection of peripheral blood mononuclear cells (PBMCs). PBMCs were transduced with RV-SFG.CD19.CD28.4-1BBzeta retroviral vector supernatant supernatant (provided by Prof. Malcolm Brenner, Baylor College of Medicine, Houston, Texas, USA) after three days of activation with anti-CD3 and anti-CD28 antibodies (MACS GMP Pure, Miltenyi Biotec, Bergisch Gladbach, Germany). RV-SFG.CD19.CD28.4-1BBzeta carries an anti-CD19 scFv derived from the FMC63 antibody inserted to the SFG retroviral backbone. The transmembrane domain is derived from CD28, the hinge domain from the human IgG1-CH2CH3 domain and 4-1BB is inserted between the CD28 and CD3ζ (CAR structure displayed in Additional file 1: Figure S1). Transduced cells were cultured in complete medium supplied with interleukine (IL)-7 (10 ng/mL) and IL-15 (5 ng/mL) (CellGenix, Freiburg, Germany) for a total of 13 days at the GMP Core Facility of the Internal Medicine V Department of the Heidelberg University Hospital (were evaluated) as descibed . Medium change was performed on days 7 and 10. Cells were cryopreserved using an automated device (Biofreeze BV 40 Consarctic, Westerngrund, Germany). Transduction efficiency was assessed using flow cytometry (FACS Canto, BD Biosciences, Franklin Lakes, NJ, USA). After testing for sterility (Ph. Eur. 2.6.1), mycoplasma (Ph. Eur. 2.6.7) and endotoxin (Ph. Eur. 2.6.14), products were released for administration.
CART treatment and follow-up, evaluation of toxicity and outcome
Patients received the respective dose of HD-CAR-1 CARTs on day 0 after lymphodepletion (fludarabine 90 mg/m2 and cyclophosphamide 1500 mg/m2). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to the consensus guidelines of the American Society for Transplantation and Cellular Therapy (ASTCT)  and managed according to institutional guidelines and as published . Tumor lysis syndrome (TLS) was graded as described . Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. B cell aplasia was defined as B cell count in the PB below 100/µl as assessed by flow cytometry. Lymphodepletion, CART administration and safety monitoring were performed as inpatient procedures with mandatory hospitalization from day -6 through day + 14. Following patient discharge, patients presented in the outpatient department according to the study visit schedule .
Clinical efficacy of HD-CAR-1 treatment was assessed according to response criteria defined for ALL [17, 18], i.e., bone marrow (BM) aspiration and/or radiologic imaging in case of extramedullary disease.
Assessment of CART frequencies
HD-CAR-1 CART frequencies were quantified by single-copy gene (SCG)-based duplex quantitative PCR (SCG-DP-PCR) amplifying simultaneously the human SCG ribonuclease (RNase) P RNA component H1 (RPPH1) and the FMC63 domain of the CAR transgene as described .
Assessment of cellular composition of CART products and patient samples
From ten HD-CAR-1 patients (unique patient number (UPN)#1-#7 and UPN#9-#11), PBMCs of the manufactured CART product and of peripheral blood (PB) samples collected after CART treatment were analyzed using 35-parametric spectral flow cytometry analysis. PBMCs derived from buffy coats of three healthy donors served as controls (used antibodies summarized in Additional file 1: Table S1).
Using the Spectre package, CART product and PBMC data were merged into a single data table, with keywords denoting the sample, group and other metadata added to each row (cell). Since data were acquired over the course of two days, batch alignment was performed by computing quantile conversions using reference samples recorded with each batch, and then applied to the samples in each batch using CytoNorm  in Spectre. The batch-corrected values were used for all downstream computations including clustering and differential expression analyses.
Analysis of T cells: For detailed clustering and subset annotation of individual T cell populations (CD4 + and CD8 + T cells), the cluster function from the CATALYST package  (version 1.18.1) was used, which performs a FlowSOM clustering and ConsensusClusterPlus metaclustering. Markers that were included for clustering were specified and were dependent on the respective T cell population excluding cells expressing the CAR.
For cellular visualizations, the dimensionality reduction algorithm Uniform manifold approximation and projection (UMAP)  was used on downsampled data, taking surface expression of used markers into consideration.
Analysis of CAR T cells: For analysis of CD4 + or CD8 + CARTs, the CD4 + and CD8 + T cell clusters were selected and the surface expression of the CAR detection marker was used to gate CAR + T cells. Within the CD4 + or CD8 + T cell compartments, cells were gated using the same cutoffs for every sample. Due to spectral spillover, different cutoffs for the CD4 + and CD8 + compartment were applied.
For principal component analysis (PCA), the cell-type frequencies for each sample were used as input. Cell-type frequencies were calculated sample-wise by dividing the number of cells of per population by the total number of cells within that sample.
To perform differential expression analysis, the diffcyt package  (version 1.14.0) was used. The models and contrast matrices were set up with the createFormula and createContrast functions from the diffcyt package. For the differential abundance analysis, a generalized linear mixed model (GLMM) was used and adjusted p values (based on Benjamini–Hochberg  method) were returned. For differential expression analysis of CD39 on cells of non-responders or responders, a linear mixed model (LMM) was applied and the unadjusted p value was reported.
Differential abundance analyses were performed by calculating the frequency of cells per population out of the total CD45 + cells per sample or the frequency of cells per CD4 + or CD8 + T cell subset out of all CD3 + TCRab + T cells, respectively. For comparisons of responders versus non-responders, the mean frequency for every population in non-responders was calculated. Then, frequencies for every population in responders were divided by the corresponding mean frequency from non-responders as determined in the step before. Likewise, for comparisons of CART recipients versus healthy donors, the mean frequency for every population in healthy donors was calculated. Then, frequencies for every population in CAR recipients were divided by the corresponding mean frequency from non-responders as determined in the step before. Sample-specific fold changes were log2-transformed and visualized as boxplots.
Statistics were calculated using Prism Software (GraphPad Software Inc., version 8.2.2). Progression-free survival (PFS) was calculated from the date of CART administration until the date of clinical progression, relapse or death, respectively. Differences between survival curves were descriptively calculated by log-rank testing. A p value < 0.05 was considered statistically significant.
Between September 2018 and January 2022, 15 patients with r/r ALL were enrolled (Fig. 1). The patient baseline characteristics are detailed in Table 1. Median age of patients was 41 (range 21–67) years. Median time from initial diagnosis to CART administration was 22 (range 5–117) months, and patients had received a median of 4 (range 2–9) prior treatment lines, including allogeneic stem cell transplantation (alloSCT) in 12 patients (80%). None of the patients received immune suppression at the time of leukapheresis or had signs of active graft-versus host disease (GvHD). All patients were complete donor chimeras at the time of leukapheresis.
Feasibility of HD-CAR-1 CART manufacturing
Leukapheresis and manufacturing of CARTs were successful for all enrolled patients. Due to low T cell counts in the PB of one patient (UPN#12), two consecutive CART production cycles had to be performed. Median duration of CART manufacturing was 10 (range 10–14) days. Median transduction efficiency was 52.7% (range 39.3–66.9%) with a viability of CARTs of > 85%. CART production details are summarized in Additional file 1: Table S2.
Of 15 patients, six patients received bridging therapy between leukapheresis and lymphodepleting therapy. Thirteen patients received HD-CAR-1 CARTs. (UPN#14 and UPN#15 did not receive CARTs due to progressive disease (PD) during CART manufacturing.) Three patients were treated with CARTs at dose level (DL) 1 (1 × 106 CARTs/m2), DL2 (5 × 106 CARTs/m2) and DL4 (5 × 107 CARTs/m2). Four patients were treated at DL3 (2 × 107 CARTs/m2) (Fig. 1). Ten patients reached end of study (EOS) on day 90 after CARTs. Three patients did not reach EOS due to PD (n = 2) at day 23 (UPN#8) and day 76 (UPN#3), respectively, and due to fatal septic organ failure (n = 1; UPN#12) on day 39 (Table 2).
Treatment with HD-CAR-1 CARTs was well tolerated (Table 2): None of the patients developed ICANS. Two patients (UPN#1 and UPN#6) developed grade I CRS with symptoms limited to fever that resolved with supportive treatment only and two patients (UPN#8, UPN#12) developed grade II CRS and received treatment with tocilizumab. UPN #8 additionally received steroids. One patient (UPN#5) developed febrile temperatures eventually attributable to Staph. epidermidis bacteremia that resolved with targeted antibiotic treatment (Additional file 1: Table S3). Higher-grade CRS, i.e., grade ≥ III, was not observed in any patient.
Patient #8, who suffered from multiple extramedullary ALL lesions prior treatment (Table 1), developed fever and mild hypoxia three days after CART administration suggestive for CRS. With high ferritin, triglycerides and sCD25, a concomitant hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) was suspected. Several doses of tocilizumab and steroids were administered. Due to further clinical deterioration including kidney failure, eventually PD was suspected. A BM biopsy performed on day 10 confirmed PD with almost 100% infiltration of the BM with ALL blasts. CRS symptoms and kidney failure were retrospectively attributed to an overlapping TLS. The patient was subsequently treated with inotuzumab-ozogamicin and received an alloSCT from a matched-related donor, but eventually died 58 days after CART infusion.
Patient #12 received CARTs 16 months after a mismatched unrelated donor alloSCT that had been complicated by a grade 3 gastrointestinal (GI) GvHD . On day 8, the patient developed CRS grade II and received tocilizumab. On day 19, the patient displayed an enterocolitis that evolved into an E. coli sepsis and progressed to septic shock with disseminated intravascular coagulation (DIC) and multi-organ failure. The patient died on day 39. Autopsy revealed that the enterocolitis had most probably been provoked and aggravated by GI-GvHD exacerbation. Elevated CART expansion was neither observed in the afflicted parts of the gut mucosa, nor in ascites/pleural effusion as proven by post-mortem quantitative PCR.
Cytopenia, B cell aplasia and infectious complications
Cytopenia, B cell aplasia and recovery of neutrophil counts are depicted in Fig. 2A, B. Persistent, i.e., beyond EOS, high-grade (≥ III) neutropenia was observed in two of nine evaluable patients (22%). Grade III neutropenia and thrombocytopenia were observed in UPN#4 who had low blood counts already before CARTs. Grade III neutropenia in UPN#2 persisted until an alloSCT, which was performed on day 126. No higher-grade anemia was observed.
Ten patients (77%) had low B cell counts already prior CARTs, most likely due to pretreatment with blinatumomab (n = 8) or cytoreductive bridging treatment (n = 4) (Table 1). At EOS, all evaluable patients (n = 9; UPN#9 not shown due to PD at EOS) had ongoing B cell aplasia (Fig. 2A), even though recovered levels of immunoglobulins were detectable in six patients (data not shown).
Until EOS, two patients (UPN#11 and UPN#13) developed respiratory infections that required oral antibiotics. One patient (UPN#1) was diagnosed with respiratory syncytial virus (RSV) that resolved with supportive care only. No patient with a prior alloSCT reactivated with cytomegalovirus (CMV) or Epstein–Barr virus (EBV).
Two patients who had undergone a prior alloSCT developed GvHD after CART treatment. UPN#6 displayed a GvHD of the lung, and a preexisting GvHD of the GI tract exacerbated in UPN#12 (see above). No non-hematologic (≥ grade III toxicity not preexisting or attributed to underlying malignancy) or hematologic (grade IV cytopenia (except lymphopenia) persisting beyond day 30 post-CARTs) dose-limiting toxicity (DLT) occurred. Toxicities after CAR T cells showed no association with the administered CAR T cell dose. Toxicities are summarized in Additional file 1: Table S3.
Overall, ten patients (77%) achieved a complete remission (CR) as best response. Seven patients (54%) attained MRD negativity. At EOS, 10 patients were evaluable for response: eight patients (80%) achieved CR, with five patients (50%) confirmed to be MRD-negative. Median overall survival (OS) at 12-month follow-up was not reached (Fig. 3A), and median PFS was reached on day 120 (Fig. 3B). In patients who achieved a MRD-negative CR at EOS (n = 5), 100% OS (Fig. 3C) and 60% PFS (Fig. 3D) at 1-year follow-up were higher compared to patients that failed MRD clearance (n = 8) (OS 38%; PFS 12.5%; OS p = 0.08; PFS p = 0.0047). Three patients received a second CART administration (UPN#1, #4, #6) that eventually mediated MRD-negative CR in two patients (UPN#4 and UPN#6). Three patients underwent alloSCT after HD-CAR-1 treatment (first alloSCT, n = 1 (UPN#8); second alloSCT, n = 2 (UPN#2, UPN#10)). Evolution of patients within one year after HD-CAR-1 treatment is depicted in Fig. 3E. Of the patients that reached EOS (n = 10), two patients have died from PD (UPN#1) and complications after an alloSCT (UPN#2), respectively, two patients are alive with disease (UPN #5,10), two patients are in MRD-positive (UPN#7,9) and four patients in MRD-negative CR (UPN#4,6,11,13). With exception of UPN#6, relapses remained positive for CD19 expression (UPN#3 not assessed for CD19 status at relapse).
Response to treatment was associated with CART doses: Patients that were treated with higher CART doses, i.e., DL3 and DL4, showed a trend toward superior OS (Fig. 3F) and PFS (Fig. 3G) compared to patients that received lower CART doses, i.e., DL1 and DL2.
PB CART expansion was observed in all patients immediately after CART administration. At EOS, CARTs were still detectable in seven (78%) of the evaluable patients (Fig. 4A). Higher CART doses (DL3, DL4) resulted in higher and prolonged expansion levels, whereas loss of detection occurred in patients that had received lower CART doses (DL1: UPN#1, #3, DL2: UPN#6) (Fig. 4B). Patients reaching expansion levels exceeding the median of 22.350 CART/µg DNA PBMC within the first month after treatment were more likely to respond than patients who displayed CART expansion below the median (Fig. 4C).
Cellular landscape of the CART product and the PB of patients after CART treatment
We used high-dimensional flow cytometry to characterize CART products (Fig. 5) and PB composition (Fig. 6) of treated patients. The CART product of analyzed patients (n = 10) contained mostly CD4 + and CD8 + T cells. Also, minor fractions of γδ-T cells and natural killer (NK) cells were identified (Fig. 5A, Additional file 1: Fig. S1A). All CART products contained CAR-positive T cells (Additional file 1: Table S2). Unsupervised clustering and dimensionality reduction of the CD4 + and CD8 + T cell compartments revealed differences in the cellular composition of the CART product in responders and non-responders (Fig. 5B, C): In responders, higher frequencies of CD39-negative effector memory-like CD4 + and CD8 + T cells were observed, whereas non-responders displayed higher levels of CD39-positive effector memory-like T cells (Fig. 5C, D, F). In fact, CD39 expression of all T cells in both CD4 + and CD8 + CART product subsets was elevated in non-responders (Fig. 5E, G), suggesting association of CD39 expression in the CART product with positive therapeutic outcome.
As for analysis of PBMCs obtained after CART administration, non-responders displayed elevated levels of monocytes, whereas responders showed a tendency toward higher CD8 + T cell and γδ-T cell frequencies (Fig. 6A, B). Expectedly, B cells in the highly-pretreated CART recipients were almost completely absent when compared to healthy donors (Additional file 1: S2B and Fig. 2A). Notably, the cellular landscape of patient #11 who remains in ongoing CR after CARTs (without further treatment (Fig. 3E)) was similar to the physiological cellular composition of healthy donors (Additional file 1: S2F). Unsupervised clustering and dimensionality reduction of CD4 + and CD8 + T cell subsets revealed well-known T cell differentiation states of CAR-negative, endogenous T cells and CAR-positive T cells (Fig. 6C, D). Both CD4 + and CD8 + CARTs of responders adopted to a higher degree effector memory and effector T cell states, whereas CARTs of non-responders predominantly adopted central memory phenotypes with high PD-1 expression (Fig. 6E, F). Similar findings were observed in the endogenous T cell compartments (Additional file 1: Fig. S2C–E).
Despite novel therapeutic options for treatment of r/r ALL patients [27,28,29], the outcome for older patients remains poor [30,31,32]. Here, we treated adult ALL patients with escalating doses of CD19-specific third-generation CARTs. For all patients, CART products were successfully manufactured. Despite low CART doses administered and a heavily pre-treated patient cohort, a CR rate of 80% including 50% MRD-negative CR was achieved. At 12 months, 38% of evaluable patients remained progression-free and median OS was not reached. Patients who achieved an initial MRD-negative CR did not reach median PFS and were all alive at 1-year follow-up.
The CAR construct used within HD-CAR-1 has already been evaluated in the context of two clinical trials that focused on patients with non-Hodgkin’s lymphoma (NHL). Also, five adult ALL patients (n = 1 , n = 4 ) were included. No response in the single ALL patient  and CR in 50% (two of four ALL patients)  were reported, although results were limited by the small patient number.
Result of HD-CAR-1 is in line with previous trials of second-generation CARTs in adult ALL patients: Park et al. reported a CR rate of 83% (n = 53), with 50% OS and 30% event-free survival (EFS) one year after treatment . In the ZUMA-3 trial resulting in the approval of Brexucabtagene autoleucel for treatment of adult r/r ALL patients in 2021, a CR rate of 71% (n = 55) with 12-month OS of 75% and EFS of 50% was observed. These results might be at least in part be attributable to the strict exclusion criteria in the ZUMA-3 trial of included patients . Frey et al. reported a CR rate of 69% (n = 35) with OS of 47% and EFS of 31% at two-year follow-up. In this latter trial, high-dose (5 × 108), fractionated CART administration (n = 20) resulted in unmet median OS and EFS one year after treatment. Of note, only 25% of patients had received a prior alloSCT .
Relapses post-CARTs have been reported in 30 to 60% of ALL patients [33, 36,37,38,39]. Also in HD-CAR-1, 50% of patients with CR at EOS, have relapsed in the first year after treatment and three patients have received a consecutive alloSCT after HD-CAR-1 treatment. In line with data on the ZUMA-3 trial , efficacy of HD-CAR-1 CARTs was limited in patients with extramedullary disease: Only one patient (UPN #13) with extramedullary disease at CART treatment did not relapse after CART treatment, underlining the difficulties of treatment of this patient subgroup.
Of note, HD-CAR-1 appears to be associated with a highly favorable toxicity profile, even at high-dose levels: No ICANS or higher-grade CRS occurred, and only low-grade (I-II°) CRS was observed in 31% of the patients. Prior alloSCT was associated with fatal exacerbation of a most likely preexisting GvHD in one patient. Although an immunogenic effect of CARTs cannot be excluded, GvHD might have been rather triggered substantially by preceding therapies including inotuzumab ozogamicin and blinatumomab.
CD28-costimulation has been associated with rapid expansion and marked anti-tumor efficacy [42,43,44], and 4-1BB has been shown to enhance proliferation, to reduce exhaustion and to mediate long-term CART persistence [45,46,47]. In fact, we observed fast expansion of HD-CAR-1-CARTs. In contrast to loss of CARTs in the PB of patients treated in ZUMA-3 on day 28 , CARTs were durably detected in HD-CAR-1 patients. In line with others, initial MRD-negative response [38, 49] and higher doses of administered CARTs  resulted in higher CART frequencies and improved outcome.
High-resolution immunophenotyping revealed an immune cell repertoire of responders characterized by general activation of T cells. In contrast to others, we observed no influence on response by myeloid subtypes  or CD4 + /CD8 + T cell ratio [50, 51]. Interestingly, the patient with the most durable response to treatment (UPN#11) displayed a distribution of immune cells in his PB which resembled the cellular composition of the PB of healthy donors. In patients responding to CART therapy, we observed a higher number of γδ T cells within collected PBMCs. In fact, infiltration of malignancies with γδ T cells is associated with favorable prognosis  and in the allo-SCT setting, γδ T cells have been associated with enhanced anti-tumor response, improved OS and reduced occurrence of GvHD [53, 54].
Within the CART product, expression of CD39 on effector T cells predicted response: Low levels of this T cell subset were observed in responders, high levels in non-responders. CD39 is expressed on T cell subsets [55, 56], and its expression on CD8-positive T cells has been associated with T cell exhaustion [57, 58]. While CARTs with a less differentiated phenotype, e.g., central memory or naïve CARTs, mediate better expansion, persistence and antitumor activity [59, 60], T cell exhaustion is associated with inferior response [61, 62]. In the context of CARTs, CD39 expression has been linked to reduced CART expansion [63, 64]. Here, we confirm clinically that CD39 within the CART product might be highly relevant to predict outcome in CART patients. In contrast to other molecules such as PD-1 that have been identified not only in CART samples but also in healthy individuals , CD39 might constitute a more specific marker for T cell exhaustion.
In summary, administration of third-generation HD-CAR-1 CARTs was remarkably safe and of promising efficacy. Responses correlated with MRD clearance and were dose-dependent. Lack of CD39 expression on T cell subsets within the CART product was associated with improved anti-leukemic activity of CARTs. HD-CAR-1 appears to be a promising step toward safe and effective ALL eradication in older patients.
Availability of data and materials
The datasets used and/or analyzed within this study as well as materials are available from the corresponding author on request.
Acute lymphoblastic leukemia
Allogeneic stem cell transplantation
American Society for Transplantation and Cellular Therapy
Chimeric antigen receptor
Chimeric antigen receptor T cells
Cluster of differentiation
- c max :
Cytokine release syndrome
Common Terminology Criteria for Adverse Events
Disseminated intravascular coagulation
End of study
Generalized linear mixed model
Good manufacturing practice
Heidelberg CAR trial 1
Immune effector cell-associated neurotoxicity syndrome
Linear mixed model
Macrophage activation syndrome
Minimal residual disease
Peripheral blood mononuclear cell
Principal component analysis
Respiratory syncytial virus
Refractory and/or relapsed
Single-copy gene-based duplex quantitative PCR
Tumor lysis syndrome
Heidelberg University Hospital
Uniform manifold approximation and projection
Unique patient number
European Medicines Agency. Yescarta - axicabtagene ciloleucel. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta.
European Medicines Agency. Kymriah - tisagenlecleucel. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah.
European Medicines Agency. Tecartus - brexucabtagene autoleucel. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus.
European Medicines Agency. Breyanzi - lisocabtagene maraleucel. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi.
Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360–5.
Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, et al. Redirecting T cells to glypican-3 with 4–1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity. Hum Gene Ther. 2017;28(5):437–48.
Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep. 2017;7(1):14366.
Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, et al. 4–1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010;21(1):75–86.
Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4–1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413–20.
Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B Cell Non-Hodgkin’s lymphomas. Mol Ther. 2018;26(12):2727–37.
Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185–94.
Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, et al. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4–1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open. 2019;9(5):e026644.
Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, Hückelhoven-Krauss A, Kunz A, Gern U, Michels B, Hinkelbein M, Mechler S, Richter P, Müller-Tidow C, Schmitt M, Schmitt A. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy. 2019;21(5):566–78. https://doi.org/10.1016/j.jcyt.2019.02.013.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38.
Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810–6.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Kunz A, Gern U, Schmitt A, Neuber B, Wang L, Hückelhoven-Krauss A, et al. Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients. Mol Ther Methods Clin Dev. 2020;17:448–54.
Ashhurst TM, Marsh-Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al. Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. Cytometry A. 2021;101:237–53.
Nowicka M, Krieg C, Crowell HL, Weber LM, Hartmann FJ, Guglietta S, et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res. 2017;6:748.
Weber LM, Nowicka M, Soneson C, Robinson MD. diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. Commun Biol. 2019;2:183.
Van Gassen S, Gaudilliere B, Angst MS, Saeys Y, Aghaeepour N. CytoNorm: a normalization algorithm for cytometry data. Cytometry A. 2020;97(3):268–78.
McInnes L, Healy J, Saul N, Großberger L. UMAP: uniform manifold approximation and projection. J Open Source Softw. 2018;3:861.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289–300.
Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transpl Proc. 1974;6(4):367–71.
Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2021;128:529–35.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):573–9.
Gokbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–33.
Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–66.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38(5):415–22.
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.
Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66–81.
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652–63.
Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643–50.
Schubert ML, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, et al. Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(9):1575–80.
Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995–1004.
Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006;20(10):1819–28.
Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415–28.
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–90.
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–64.
Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, et al. 4–1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179(7):4910–8.
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22.
Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Méchinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383–93.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38.
Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492–500.
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–45.
Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996;5(5):503–9.
Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39(12):751–7.
Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225–32.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–65.
Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 Expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11(10): e1005177.
Qi Y, Xia Y, Lin Z, Qu Y, Qi Y, Chen Y, et al. Tumor-infiltrating CD39(+)CD8(+) T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunol Immunother. 2020;69(8):1565–76.
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71.
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3(4):356–67.
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8(23):eabj2820.
Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878–87.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(9):932–44.
Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, et al. 4–1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021;9(10).
Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, Doho GH, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol. 2011;186(7):4200–12.
Triana S, Vonficht D, Jopp-Saile L, Raffel S, Lutz R, Leonce D, et al. Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states. Nat Immunol. 2021;22(12):1577–89.
We thank the patients and their families.
Open Access funding enabled and organized by Projekt DEAL. This work was supported by the National Center of Tumor Diseases (NCT), by the German Cancer Research Institute (DKFZ), by the Jochen Siebeneicher Foundation and by a personal donation from Dr. h.c. Karl Schlecht. MLS is supported by the Olympia Morata Program of the Medical Faculty of the University of Heidelberg (grant no. OM 09/2019). AN is supported by the Carreras leukemia foundation (AH06-01). FL receives support from the Frankfurter Förderung “Nachwuchswissenschaftler” and the EUTOS funding program.
AS: Travel grants from Hexal and Jazz Pharmaceuticals. Research grant from Therakos/Mallinckrodt. Consultancy BMS, Janssen-Cilag. Co-founder and part-time employee of TolerogenixX LtD. of TolerogenixX Ltd. CMT: research support from Bayer AG. Advisory board member Pfizer, Janssen-Cilag GmbH. Grants and/or provision of investigational medicinal products from Pfizer, Daiichi Sankyo, BiolineRx. FL: Advisory roles for Novartis, Incyte, Sanofi Aventis and Bristol-Myers Squibb. GB: Research support from Novartis; Consultancy for Novartis, Pfizer, Gilead, Celgene; Honoraria from Jazz, Celgene, Gilead; Travel support from Neovii, Jazz, Gilead. JC: Travel grants: Pfizer, Ipsen, Medac; Adboard: Pfizer, Merck, Ipsen, MSD; Consultancy: Pfizer, Merck, Medac. JK: Consultancy Novartis, Global Blood Therapeutics, bluebird bio. MB: consulting fees from Amgen and PRMA, research funding from Amgen, honoraria/travel grants from Jazz, Celgene, Novartis, Pfizer and Amgen, advisory board member for Incyte and Amgen. MLS: consultancy for Kite/Gilead, Takeda. MS: research grants from Apogenix, Hexal and Novartis. Travel grants from Hexal and Kite. Financial support for educational activities and conferences from bluebird bio, Kite and Novartis. Advisory board member of MSD. (Co-)PI of clinical trials of MSD, GSK, Kite and BMS. Co-Founder and shareholder of TolerogenixX Ltd. PD: consultancy AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. None of the mentioned sources supported the work described within this manuscript. PDe: honorarium from MSD. PWu: Research support from the German Red Cross Blood Service Baden-Württemberg – Hessen gGmbH. Advisory Board Member of Sanofi-Aventis. TS: Consultant AbbVie, Takeda, Astellas, Amgen, Bristol-Myers Squibb, Gilead, Ridgeline Discoveries. Honorarium: Pfizer, AbbVie, Jazz Pharmaceuticals. Financial support congress participation: AbbVie, Jazz Pharmaceuticals., ADH, AHK, AKei, AKul, AKun, AN, BM, BN, DH, DV, DW, FK, JF, LJS, LW, MG, MRi, NG, PP, PW, SH, SLa, SY: none.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Antibodies used for assessment of cellular composition of CART products and of PB samples of patients after CART treatment. Table S.2 Characterization of the leukapheresis and the HD-CAR-1 product by conventional flow cytometry. Table S.3 HD-CAR-1 adverse events according to CTCAE. Figure S.1 Structure of the RV-SFG.CD19.CD28.4-1BBzeta retroviral vector. Figure S.2 Additional data on the cellular composition of CART products and of corresponding PB samples.
About this article
Cite this article
Schubert, ML., Schmitt, A., Hückelhoven-Krauss, A. et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol 16, 79 (2023). https://doi.org/10.1186/s13045-023-01470-0
- Acute lymphoblastic leukemia (ALL)
- Third-generation chimeric antigen receptor (CAR) T cells
- Investigator-initiated trial (IIT)
- CART-associated toxicities
- Cytokine release syndrome (CRS)
- Immune effector cell-associated neurotoxicity syndrome (ICANS)